{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"31"},{"groupId":"OG006","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"39"},{"groupId":"OG003","value":"42"},{"groupId":"OG004","value":"42"},{"groupId":"OG005","value":"42"},{"groupId":"OG006","value":"37"}],"units":"Participants"}],"description":"The number of patients who reported at least a grade 3 adverse event were assessed in those who initiated treatment.","groups":[{"description":"Patients randomized to Cedinarib reference arm during the recruitment period (09/04/2018-06/17/2019). Patients receive Cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCediranib: Given PO\n\nCediranib Maleate: Given PO\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA","id":"OG000","title":"Arm I (Cediranib maleate_Group1)"},{"description":"Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA\n\nOlaparib: Given PO","id":"OG001","title":"Arm II (Olaparib)"},{"description":"Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCediranib: Given PO\n\nCediranib Maleate: Given PO\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA\n\nOlaparib: Given PO","id":"OG002","title":"Arm III (Cediranib Maleate, Olaparib)"},{"description":"Patients receive olaparib PO BID on days 1-28 and capivasertib PO BID on days 1-4 each week. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCapivasertib: Given PO\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA\n\nOlaparib: Given PO","id":"OG003","title":"Arm IV (Olaparib, Capivasertib)"},{"description":"Patients receive olaparib PO BID on days 1-28 and durvalumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nComputed Tomography: Undergo CT scan\n\nDurvalumab: Given IV\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA\n\nOlaparib: Given PO","id":"OG004","title":"Arm V (Olaparib, Durvalumab)"},{"description":"Patients receive cediranib maleate PO QD on days 1-5 each week and durvalumab IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCediranib Maleate: Given PO\n\nComputed Tomography: Undergo CT scan\n\nDurvalumab: Given IV\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA","id":"OG005","title":"Arm VI (Cediranib Maleate, Durvalumab)"},{"description":"Patients randomized to Cedinarib reference arm during the recruitment period (08/16/2021-06/28/2023).\n\nPatients receive cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity. Additionally, patients undergo blood sample collection, bone marrow aspiration and biopsy, CT, Echo or MUGA on study.\n\nBiospecimen Collection: Undergo blood sample collection\n\nBone Marrow Aspirate: Undergo bone marrow aspiration and biopsy\n\nBone Marrow Biopsy: Undergo bone marrow aspiration and biopsy\n\nCediranib: Given PO\n\nCediranib Maleate: Given PO\n\nComputed Tomography: Undergo CT scan\n\nEchocardiography: Undergo Echo\n\nMultigated Acquisition Scan: Undergo MUGA","id":"OG006","title":"Arm VII (Cediranib maleate_Group2)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who initiated assigned treatment.","reportingStatus":"POSTED","timeFrame":"Toxicity was assessed every other week for the first 8 weeks of study therapy and every 8 weeks after the completion or termination of study therapy up to 50 months.","title":"Incidence of Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}